An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

NCT05084261 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: BT051 200 mg
DRUG: BT051 800 mg
DRUG: BT051 3200 mg
DRUG: Matching Placebo

Sponsor

Adiso Therapeutics